Vaishalee P. Kenkre

University of Wisconsin Carbone Cancer Center — United States

Medicine · Health Sciences

24h-index3.3kcitations143works5.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(99), Chronic Lymphocytic Leukemia Research(56), CAR-T cell therapy research(33), Viral-associated cancers and disorders(26), CNS Lymphoma Diagnosis and Treatment(17)

Publications143 total

Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network·2026
Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity
Journal of Clinical Oncology·2025
American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma
Transplantation and Cellular Therapy·2025Open Access
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART
UNC Libraries·2025Open Access
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium
Blood Advances·2025Open Access
Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy
Blood·2025
Socioeconomic disadvantage, as measured by area deprivation index (ADI), impacts survival in patients with relapsed/refractory aggressive lymphoma treated with CART
Blood·2025Open Access
Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL
Blood·2025
Graft vs host disease outcomes in early tacrolimus withdrawal following allogeneic hematopoietic stem cell transplant
Blood·2025Open Access
Infections in patients with aggressive B-cell lymphomas treated with CD3xCD20 bispecific antibodies
Blood·2025Open Access
Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians
Blood·2025Open Access
Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium
Blood·2025Open Access
Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium
Blood·2025Open Access
Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study
Blood·2025Open Access
Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium
Blood Advances·2025· 1 citedOpen Access
ABCL-1407: Split-Dose R-CHOP With Interim De-Escalation of Therapy in Elderly Patients With Diffuse Large B-cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-1407 Split-Dose R-CHOP With Interim De-Escalation of Therapy in Elderly Patients With Diffuse Large B-cell Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART
Cancers·2025Open Access
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy
Blood Cancer Journal·2025· 9 citedOpen Access
Clinical Outcomes of Transformed Marginal Zone Lymphoma and Richter Transformation with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
Transplantation and Cellular Therapy·2025
page 1 of 8Next →

Frequent Co-authors

Narendranath Epperla(15), Mehdi Hamadani(12), Deepa Jagadeesh(11), Reem Karmali(11), Nirav N. Shah(11), Sairah Ahmed(10), Veronika Bachanová(10), Jonathon B. Cohen(9), Umar Farooq(9), Nishitha Reddy(9), Kevin A. David(9), Brad S. Kahl(9), Kristie A. Blum(8), Leo I. Gordon(8), Alex F. Herrera(8), Nadia Khan(8), Jane N. Winter(8), Kwang Woo Ahn(8), Sonali M. Smith(8), Timothy S. Fenske(8)